initial public offerings (IPOs) trading on American exchanges

Monday, January 5, 2015

Intersect ENT (XENT) began trading on the NASDAQ on 24 July 2014


Intersect ENT, Inc. is a commercial-stage drug-device company. The Company has developed a drug-eluting bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ear, nose and throat (ENT), physicians to improve patient care. The Company’s initial products PROPEL and PROPEL mini, is a drug-eluting implants approved by the United States Food and Drug Administration (FDA), for use in patients with chronic sinusitis. The Company’s two commercial products PROPEL and PROPEL mini, are designed to improve the outcomes of sinus surgery by reducing postoperative inflammation and scarring from the underlying condition, as well as the surgery.


1555 Adams Dr
MENLO PARK, CA 94025-1439
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-64.67%-102.44%
Operating margin-64.85%-100.20%
EBITD margin--97.38%
Return on average assets-60.04%-129.99%
Return on average equity--

No comments:

Post a Comment